HealthcarePress Releases

Plasmid DNA Manufacturing Market Trending Technologies with 21.7% of CAGR by 2030

Share This Article

The plasmid DNA manufacturing market was exceeded US$ 306.4 million in 2020 and is projected to reach US$ 2.1 billion by 2030, expanding at an annual CAGR of 21.7 percent, according to a 2021 study by Precedence Research, the Canada-based market Insight Company. The report contains 150+ pages with detailed analysis.

The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030. The dairy products market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1299

The plasmid DNA manufacturing market has witnessed an upsurge in the global biopharmaceutical industry. The growing adoption of plasmid DNA for developing vaccines and drugs for various diseases in the biopharmaceutical industry is significantly propelling the demand for the plasmid DNA. Furthermore, the growing adoption of gene therapy for the treatment of various infectious and genetic disorder has exponentially contributed towards the growth of the market in the recent years. Plasmid DNA is also extensively used in applying gene therapy to diagnose diseases in patients, fueling the demand for the gene therapy. Moreover, the growing prevalence of cancer is propelling the market growth. According to The International Agency for Research on Cancer (IARC), in 2020, the global cancer cases reached to 19.3 million and around 10 million deaths due to cancer had been recorded. Breast cancer is the dominant type of cancer with 24.5% of the total cancer cases. Hence, the growing adoption of gene therapy in the treatment of cancer is propelling the growth of the global plasmid DNA manufacturing market.

Competition Landscape

In the final section of the research report, Precedence Research provided the global plasmid DNA manufacturing market structure and a detailed competition landscape to provide a dashboard view of key players operating in the plasmid DNA manufacturing market along with their business strategies to report audiences. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the value chain of the market.

Some of the major players in the plasmid DNA manufacturing market include:

  • VGXI, Inc.
  • Akron Biotech
  • Cobra Biologics & Pharmaceutical Services
  • Aldevron
  • Plasmidfactory GmbH
  • Vigene Biosciences
  • Luminous Biosciences
  • Nature Technology Corporation
  • Delphi Genetics
  • JAFRAL Ltd.

Crucial factors accountable for market growth are:

  • Growing burden of cancer cases
  • Growing prevalence of disease
  • Growing geriatric population
  • Heavy investments on technology and innovations
  • Rising government expenditure on healthcare sector in emerging economies
  • Rapid growth of the biopharmaceutical industry
  • Growing popularity of gene therapy amongst the consumer/patients

Report Highlights

  • By product type, the viral vector segment led the global plasmid DNA manufacturing market with remarkable revenue share in 2020. The demand for the viral vector in the production of vaccines, cell therapies, and gene therapies is already very huge across the globe. The COVID-19 pandemic further boosted its increasing demand for the vaccine production.
  • By application, the gene therapy segment led the global plasmid DNA manufacturing market with remarkable revenue share in 2020.This is because of the growing confidence of the people regarding the effectiveness, reliability, and safety of the gene therapies in the treatment of various chronic and genetic diseases.
  • By disease, the cancer segment is expected to be the fastest-growing segment throughout the forecast period, owing to the increasing uses of the plasmid DNA in the development of various treatment therapies for the cancer

Market Dynamics

Drivers

The growing usage of plasmid DNA for the development of vaccines is fueling the demand. The plasmid DNA is extensively used for developing vaccines for diseases such as influenza, HIV, malaria, pathogens, and Ebola. The DNA vaccines are highly effective and hence, it is increasingly used, thereby fostering the consumption of plasmid DNA.

Restraints

Various risks related to gene therapies like mutagenesis may hamper the market growth. Further, stringent government regulations and high costs involved may restrict the adoption of gene therapies. These factors have an adverse effect on the market.

Opportunities

Growing investments and innovations in the biopharmaceutical industry to develop innovative manufacturing technologies to increase the commercial production output of the plasmid DNA may have a big impact on the market during the forecast period.

Challenges

Lack of adequate infrastructure and financial limitations poses a challenge to carry on the smooth functioning of the research and developmental activities in the field of plasmid DNA manufacturing.

Regional Snapshots

North America is the leading plasmid DNA manufacturing market. The growing investments in the development of new biopharmaceutical medicines are resulting in rise in the number of contract manufacturers in the region. Moreover, US hold the maximum intellectual property copyrights for majority of the newly developed medicines. The higher adoption rate of advanced healthcare services coupled with growing preferences for gene and cell therapies among the population is a major factor that propelled the demand for the plasmid DNA manufacturing market in North America. The continuous research and development activities towards the development of new biopharma medicines are expected to foster market growth in the forthcoming years. Along with the growth of the contract manufacturers, North America is also hub for the numerous contract research organizations that facilitates development of new medicines.

Asia Pacific is expected to witness highest growth rate throughout the forecast period owing to the growing manufacturing of plasmid DNA in the region. The world’s largest contract manufacturing company, GenScript started its operation in China by setting up a plasmid and virus facility in December 2019. This is a major development in the Asia Pacific plasmid DNA manufacturing market. Furthermore, the presence of Biocon in India and Samsung Biologics in South Korea are witnessing spike in their sales in the past few years. These factors are expected to boost the plasmid DNA manufacturing market in the region.

Market Segmentation

By Product

  • Viral Vectors
  • Plasmid DNA
  • Non-Viral
  • Electroporation
  • Lipid/Polymer
  • Nanoparticles
  • Others

By Application

  • Gene Therapy
  • DNA Vaccines
  • Immunotherapy
  • Others

By Disease

  • Infectious Disease
  • Genetic Disorder
  • Cancer

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and

Questionnaire based research etc.

  • In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

Most Asked Questions –

  • What was the market size value of the plasmid DNA manufacturing in 2020?
  • What is the expected market size by 2030?
  • What is the plasmid DNA manufacturing market growth?
  • What are the key factors that positively influence market growth?
  • Who are the prominent players in the plasmid DNA manufacturing market?

Why should you invest in this report?

If you are aiming to enter the global plasmid DNA manufacturing market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for plasmid DNA manufacturing are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Plasmid DNA Manufacturing Market, By Product

7.1. Plasmid DNA Manufacturing Market, by Product Type, 2021-2030

7.1.1. Viral Vectors

7.1.1.1. Market Revenue and Forecast (2019-2030)

7.1.2. Plasmid DNA

7.1.2.1. Market Revenue and Forecast (2019-2030)

7.1.3. Non-Viral

7.1.3.1. Market Revenue and Forecast (2019-2030)

7.1.4. Electroporation

7.1.4.1. Market Revenue and Forecast (2019-2030)

7.1.5. Lipid/Polymer

7.1.5.1. Market Revenue and Forecast (2019-2030)

7.1.6. Nanoparticles

7.1.6.1. Market Revenue and Forecast (2019-2030)

7.1.7. Others

7.1.7.1. Market Revenue and Forecast (2019-2030)

Chapter 8. Global Plasmid DNA Manufacturing Market, By Application

8.1. Plasmid DNA Manufacturing Market, by Application, 2021-2030

8.1.1. Gene Therapy

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Immunotherapy

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Plasmid DNA Manufacturing Market, By Disease

9.1. Plasmid DNA Manufacturing Market, by Disease, 2021-2030

9.1.1. Infectious Disease

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Genetic Disorder

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Cancer

9.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.3. Market Revenue and Forecast, by Disease (2019-2030)

10.1.4. U.S.

10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.1.5. Rest of North America

10.1.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.4. UK

10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.5. Germany

10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.6. France

10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.6.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.7. Rest of Europe

10.2.7.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.7.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.4. India

10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.5. China

10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.6. Japan

10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.6.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.7. Rest of APAC

10.3.7.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.7.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.4. GCC

10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.5. North Africa

10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.6. South Africa

10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.6.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.7. Rest of MEA

10.4.7.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.7.3. Market Revenue and Forecast, by Disease (2019-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.5.4. Brazil

10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.5.5. Rest of LATAM

10.5.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.5.3. Market Revenue and Forecast, by Disease (2019-2030)

Chapter 11. Company Profiles

11.1. VGXI, Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Akron Biotech

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Cobra Biologics & Pharmaceutical Services

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Aldevron

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Plasmidfactory GmbH

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Vigene Biosciences

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Luminous Biosciences

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Nature Technology Corporation

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Delphi Genetics

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. JAFRAL Ltd.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1299

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Follow us on LinkedIn | Twitter | Facebook

Show More

Market Stats News

Market Stats News is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services, we aim at connecting an organization’s goal with lucrative prospects globally.

Related Articles

Back to top button